Related Experiment Video
Updated: Feb 9, 2026

Author Spotlight: Advancing Diabetes Research with Static Exercise Training in Mice
Published on: March 29, 2024
Treatment of type 2 diabetes: future approaches
Clifford J Bailey1, Caroline Day1
1Department of Biomedical Sciences, School of Life and Health Sciences, Aston University, Birmingham, UK.
Introduction Or Background:
Type 2 diabetes, which accounts for ~90% of all diabetes, is a heterogeneous and progressive disease with a variety of causative and potentiating factors. The hyperglycaemia of type 2 diabetes is often inadequately controlled, hence the need for a wider selection of glucose-lowering treatments.
Sources Of Data:
Medline, PubMed, Web of Science and Google Scholar.
Areas Of Agreement:
Early, effective and sustained control of blood glucose defers the onset and reduces the severity of microvascular and neuropathic complications of type 2 diabetes and helps to reduce the risk of cardiovascular (CV) complications.
Areas Of Controversy:
Newer glucose-lowering agents require extensive long-term studies to confirm CV safety. The positioning of newer agents within therapeutic algorithms varies.
Growing Points:
In addition to their glucose-lowering efficacy, some new glucose-lowering agents may act independently to reduce CV and renal complications.
Areas Timely For Developing Research:
Studies of potential new glucose-lowering agents offer the opportunity to safely improve glycaemic control with prolonged efficacy and greater opportunity for therapeutic individualisation.
Insights
Effective management of type 2 diabetes is crucial for preventing complications. Newer glucose-lowering treatments offer improved efficacy and individualized care for better blood glucose control.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes is a common, progressive condition with inadequately controlled hyperglycemia.
- A wide range of glucose-lowering treatments is needed due to disease heterogeneity.
Purpose of the Study:
- To review the current landscape of glucose-lowering treatments for type 2 diabetes.
- To highlight the potential of newer agents in managing complications and individualizing therapy.
Main Methods:
- Literature search of Medline, PubMed, Web of Science, and Google Scholar.
- Analysis of studies on glucose-lowering agents, focusing on efficacy, safety, and cardiovascular/renal outcomes.
Main Results:
- Early and sustained glycemic control reduces microvascular, neuropathic, and cardiovascular complications.
- Newer agents show potential for independent cardiovascular and renal benefits, but require long-term CV safety data.
- Therapeutic positioning of novel agents is still evolving.
Conclusions:
- Optimizing glycemic control is key to preventing type 2 diabetes complications.
- Emerging glucose-lowering agents offer promise for improved efficacy, safety, and personalized treatment strategies.
- Further research is needed to confirm long-term cardiovascular safety and refine treatment algorithms.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Psychoneuroimmunology: Diabetes and Cancer

